Erica Mayer
埃丽卡·迈尔
MD, MPH
Senior Physician, Breast Oncology Program乳腺肿瘤项目高级医师
👥Biography 个人简介
Erica Mayer is a leading authority on BRCA-related and hereditary breast cancer at Dana-Farber. Her research has shaped the clinical use of PARP inhibitors in BRCA-mutated breast cancer and established survivorship and genetic testing frameworks for high-risk patients.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PARP Inhibitors in BRCA-Mutated Breast Cancer
Contributed to pivotal olaparib and talazoparib trials demonstrating PFS benefit in germline BRCA-mutated metastatic breast cancer, supporting FDA approvals.
Hereditary Cancer Risk and Survivorship
Developed patient education and risk management models for BRCA carriers, improving genetic counseling and surveillance strategies in high-risk breast cancer populations.
Representative Works 代表性著作
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation (OlympiAD)
New England Journal of Medicine (2017)
Landmark trial demonstrating olaparib superiority over chemotherapy in germline BRCA-mutated HER2-negative metastatic breast cancer.
PARP inhibition in early-stage BRCA-mutated breast cancer (OlympiA)
New England Journal of Medicine (2021)
Adjuvant olaparib significantly improved invasive DFS in high-risk germline BRCA-mutated early breast cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 埃丽卡·迈尔 的研究动态
Follow Erica Mayer's research updates
留下邮箱，当我们发布与 Erica Mayer（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment